Noesis Capital Mangement Corp reduced its holdings in Novartis AG (NYSE:NVS) by 10.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,050 shares of the company’s stock after selling 340 shares during the quarter. Noesis Capital Mangement Corp’s holdings in Novartis were worth $293,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its position in Novartis by 223.5% during the fourth quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock valued at $981,607,000 after acquiring an additional 7,902,964 shares during the period. Bank of America Corp DE grew its position in Novartis by 25.1% during the fourth quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock valued at $776,909,000 after acquiring an additional 1,817,005 shares during the period. Fisher Asset Management LLC grew its position in Novartis by 2.5% during the fourth quarter. Fisher Asset Management LLC now owns 7,609,632 shares of the company’s stock valued at $652,983,000 after acquiring an additional 184,555 shares during the period. Boston Partners grew its position in Novartis by 26.1% during the fourth quarter. Boston Partners now owns 7,046,794 shares of the company’s stock valued at $604,685,000 after acquiring an additional 1,459,845 shares during the period. Finally, FMR LLC grew its position in Novartis by 441.6% during the fourth quarter. FMR LLC now owns 7,016,047 shares of the company’s stock valued at $602,046,000 after acquiring an additional 5,720,650 shares during the period. Hedge funds and other institutional investors own 11.82% of the company’s stock.

Shares of NYSE NVS opened at $84.44 on Friday. Novartis AG has a 1-year low of $63.60 and a 1-year high of $85.08. The company has a quick ratio of 0.83, a current ratio of 0.93 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $195.06 billion, a PE ratio of 16.59, a P/E/G ratio of 1.98 and a beta of 0.66.

Novartis (NYSE:NVS) last issued its earnings results on Wednesday, April 24th. The company reported $1.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.10. Novartis had a return on equity of 16.75% and a net margin of 24.55%. The company had revenue of $11.11 billion during the quarter, compared to the consensus estimate of $11.76 billion. During the same quarter in the prior year, the business earned $1.28 earnings per share. The company’s revenue was up 1.7% compared to the same quarter last year. On average, research analysts anticipate that Novartis AG will post 5 EPS for the current fiscal year.

NVS has been the subject of a number of research reports. JPMorgan Chase & Co. reissued a “sell” rating on shares of Novartis in a research report on Tuesday, January 29th. Morgan Stanley downgraded Novartis from an “equal weight” rating to an “underweight” rating and boosted their price target for the company from $82.50 to $82.52 in a research report on Wednesday, April 10th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 11th. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target for the company in a research report on Wednesday, April 24th. Finally, Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Five research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $87.57.

ILLEGAL ACTIVITY NOTICE: “Noesis Capital Mangement Corp Has $293,000 Position in Novartis AG (NVS)” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/noesis-capital-mangement-corp-has-293000-position-in-novartis-ag-nvs/3021004.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Story: How to interpret a stock’s beta number

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.